Individualization of Immunosuppressive Therapy. III. Sirolimus Associated With a Reduced Incidence of Malignancy
Authors:
- J.F. BuellJBJ.F. Buell
- S. WoodleSWS. Woodle
- B.D. KahanBKB.D. Kahan
- 1 March 2006
- journal article
- Published by Elsevier in Transplantation Proceedings
- Vol. 38 (2) , 358-361
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Low Incidence of Malignancy among Sirolimus/Cyclosporine-Treated Renal Transplant RecipientsTransplantation, 2005
- Cancer after Kidney Transplantation in the United StatesAmerican Journal of Transplantation, 2004
- Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study ReportAmerican Journal of Transplantation, 2004
- Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy1Transplantation, 2002
- Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factorNature Medicine, 2002
- Cyclosporine induces cancer progression by a cell-autonomous mechanismNature, 1999
- Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progressionClinical Biochemistry, 1998
- Risk of neoplasia in renal transplant patientsThe Lancet, 1995
- Mechanism of action of rapamycin: New insights into the regulation of G1-phase progression in eukaryotic cells1995
- Activity of rapamycin (AY-22,989) against transplanted tumors.The Journal of Antibiotics, 1984